MF
Clinical trials for MF explained in plain language.
Never miss a new study
Get alerted when new MF trials appear
Sign up with your email to follow new studies for MF, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill for rare bone marrow cancer shows promise in shrinking spleens
Disease control Recruiting nowThis study tests a new drug called flonoltinib maleate for people with intermediate- or high-risk myelofibrosis, a rare bone marrow disorder. The main goal is to see if the drug can shrink an enlarged spleen by at least 35% and reduce symptoms like pain and fatigue. About 105 adu…
Matched conditions: MF
Phase: PHASE3 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated May 17, 2026 06:05 UTC
-
New hope for myelofibrosis patients who failed standard therapy
Disease control Recruiting nowThis study tests a new oral drug, Flonoltinib maleate, in about 64 adults with intermediate- or high-risk myelofibrosis whose disease did not respond to or stopped responding to JAK inhibitors. The main goal is to see if the drug can shrink the spleen by at least 35%. Participant…
Matched conditions: MF
Phase: PHASE2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New drug combo aims to shrink spleens and ease symptoms in myelofibrosis patients
Disease control Recruiting nowThis study tests whether adding navtemadlin to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis who didn't get enough benefit from ruxolitinib. About 600 adults with high- or intermediate-risk myelofibrosis will take part. The goal i…
Matched conditions: MF
Phase: PHASE3 • Sponsor: Kartos Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New hope for tough cancers: experimental drug JAB-8263 enters human trials
Disease control Recruiting nowThis study tests a new drug called JAB-8263 in adults with advanced solid tumors (like lung or ovarian cancer) or blood cancers (like leukemia) that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 15…
Matched conditions: MF
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New registry aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis study follows 5,000 adults with myeloproliferative neoplasms (MPNs) — rare blood cancers — to understand how symptoms change and how the disease progresses over years. Participants share their health records, insurance data, and regular surveys about how they feel. No new tr…
Matched conditions: MF
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated May 04, 2026 16:17 UTC